AustinPx Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 61

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 2

AustinPx General Information

Description

Operator of a contract development and manufacturing organization intended for analytical and formulation development services and cGMP manufacturing for small molecule drugs. The company offers preclinical services through Phase II formulation and process development and GMP manufacturing of oral dosage forms, enabling healthcare providers to focus on creating novel therapeutics from poorly bioavailable drugs to deliver clinical benefits to patients.

Contact Information

Website
www.austinpx.com
Formerly Known As
DisperSol
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 111 West Cooperative Way
  • Building 3
  • Georgetown, TX 78626
  • United States
+1 (512)
Primary Industry
Managed Care
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Vertical(s)
Manufacturing, HealthTech, Life Sciences
Corporate Office
  • 111 West Cooperative Way
  • Building 3
  • Georgetown, TX 78626
  • United States
+1 (512)

AustinPx Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AustinPx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 27-Aug-2024 Completed Generating Revenue
11. Debt - General 04-Aug-2023 Completed Generating Revenue
10. Later Stage VC 14-Mar-2023 Completed Generating Revenue
9. Secondary Transaction - Private 28-Jul-2022 Completed Generating Revenue
8. Later Stage VC (Series C) 29-Apr-2021 Completed Generating Revenue
7. Debt - PPP 10-Apr-2020 Completed Generating Revenue
6. Later Stage VC 27-Apr-2018 Completed Generating Revenue
5. Later Stage VC 31-Jan-2016 Completed Generating Revenue
4. Later Stage VC 03-Feb-2015 $10M $13.7M Completed Generating Revenue
3. Later Stage VC 10-Mar-2014 $3.02M $3.66M Completed Generating Revenue
To view AustinPx’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

AustinPx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a contract development and manufacturing organization intended for analytical and formulation development se
Managed Care
Georgetown, TX
61 As of 2024

King of Prussia, PA
 

North Brunswick, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AustinPx Competitors (2)

One of AustinPx’s 2 competitors is Center for Breakthrough Medicines, a Corporate Backed or Acquired company based in King of Prussia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Center for Breakthrough Medicines Corporate Backed or Acquired King of Prussia, PA
Ascendia Pharmaceuticals Private Equity-Backed North Brunswick, NJ
You’re viewing 2 of 2 competitors. Get the full list »

AustinPx Patents

  • 85

    Total Documents Applications and Grants

  • Total Patents Families

  • 49

    Granted

  • 19

    Pending

  • Expiring in next 12 mo

AustinPx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210087191-A1 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds, their synthesis, and use thereof Inactive 04-Dec-2020
US-20220401579-A1 Inclusion complexes of pharmaceuticals and cyclic oligomers Pending 30-Nov-2019
US-20210128536-A1 Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof Pending 01-Nov-2019
US-20220362264-A1 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof Pending 18-Mar-2019
AU-2020240017-A1 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof Inactive 18-Mar-2019 A61K31/58
To view AustinPx’s complete patent history, request access »

AustinPx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AustinPx Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Chart Venture Partners Venture Capital Minority
Research Corporation Technologies Venture Capital Minority
To view AustinPx’s complete investors history, request access »

Ready to get started?

Request a free trial

AustinPx FAQs

  • When was AustinPx founded?

    AustinPx was founded in 2007.

  • Where is AustinPx headquartered?

    AustinPx is headquartered in Georgetown, TX.

  • What is the size of AustinPx?

    AustinPx has 61 total employees.

  • What industry is AustinPx in?

    AustinPx’s primary industry is Managed Care.

  • Is AustinPx a private or public company?

    AustinPx is a Private company.

  • What is AustinPx’s current revenue?

    The current revenue for AustinPx is .

  • How much funding has AustinPx raised over time?

    AustinPx has raised $57.4M.

  • Who are AustinPx’s investors?

    Chart Venture Partners and Research Corporation Technologies have invested in AustinPx.

  • Who are AustinPx’s competitors?

    Center for Breakthrough Medicines and Ascendia Pharmaceuticals are competitors of AustinPx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »